Dysregulated expression of several proangiogenic and antiangiogenic factors has been implicated in the dysfunction of angiogenesis in systemic sclerosis (SSc). Into this complex scenario comes the study recently published in *Arthritis Research & Therapy* by Hirigoyen et al. \[[@CR1]\], who report new data implicating an inhibitory splice variant of vascular endothelial growth factor (VEGF)-A, namely VEGF~165~b, in the inhibition of angiogenesis by platelets in SSc. These findings are part of an intriguing chain of data as several studies have shown that VEGF-A, one of the most potent promoters of angiogenesis, is markedly increased in SSc skin and circulation despite clear evidence of an insufficient angiogenic response \[[@CR2], [@CR3]\]. This was considered the "SSc paradox" until it became evident recently that early studies could not distinguish between proangiogenic VEGF~165~ and antiangiogenic VEGF~165~b isoforms generated by alternative splicing in VEGF-A pre-mRNA \[[@CR4]\]. In most pathologic angiogenic conditions, such as cancers, VEGF~165~ predominates. On the contrary, this crucial balance between isoforms shifts in favor of the expression of VEGF~165~b in SSc (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR4], [@CR5]\]. VEGF~165~b appears selectively overexpressed in different cell types of SSc dermis, including endothelial cells (ECs), fibroblasts, and perivascular mononuclear inflammatory cells \[[@CR5]\]. In vitro studies further revealed that SSc dermal microvascular endothelial cells (MVECs) express and release elevated levels of VEGF~165~b \[[@CR5]\]. Moreover, the increased VEGF~165~b plasma levels in SSc correlate with the extent of nailfold capillary architectural derangement and loss, suggesting their potential utility as a biomarker reflecting disease severity \[[@CR6]\]. In this context, the study by Hirigoyen et al. \[[@CR1]\] adds new valuable information showing that, in SSc, platelets store high levels of VEGF~165~b. It could therefore be suggested that platelets may be a major source of circulating VEGF~165~b in SSc, in particular following their activation on contact with the injured endothelium.Fig. 1Schematic illustration of the mechanisms impairing VEGF-A/VEGFR-2 angiogenic signal in SSc. Angiogenesis tightly depends on the balance of proangiogenic VEGF~165~ and antiangiogenic VEGF~165~b isoforms. In angiogenic conditions, VEGF~165~ predominates, whereas in SSc the balance shifts to favor the expression of the VEGF~165~b splice variant in different cell types, such as ECs, platelets, fibroblasts, and mononuclear inflammatory cells. In ECs, binding of VEGF~165~ to both VEGFR-2 and NRP1 coreceptor activates VEGFR-2 phosphorylation and multiple downstream signaling pathways that are necessary for angiogenesis. Moreover, uPAR interacts with VEGFR-2 and recruits LRP-1 to VEGFR-2, which induces internalization of VEGF~165~-bound VEGFR-2, a key step in the proangiogenic signal. In SSc, both a switch from proangiogenic VEGF~165~ to antiangiogenic VEGF~165~b, which is unable to bind NRP1, and concomitant NRP1 downregulation due to Fli1 transcription factor deficiency result in an insufficient tyrosine phosphorylation/activation of VEGFR-2 and incomplete or transient downstream signaling along with a differential intracellular trafficking of VEGFR-2 toward the degradative pathway, ultimately leading to impaired angiogenesis. In SSc ECs, MMP-12-mediated cleavage/inactivation of uPAR may further impair the VEGF-A/VEGFR-2 system. *EC* endothelial cell, *Fli1* Friend leukemia integration 1, *LRP-1* low-density lipoprotein receptor-related protein 1, *MMP-12* matrix metalloproteinase-12, *NRP1* neuropilin-1, *SSC* systemic sclerosis, *uPAR* urokinase-type plasminogen activator receptor, *VEGF* vascular endothelial growth factor, *VEGFR* vascular endothelial growth factor receptor

The discovery of VEGF~165~b clearly adds a new fundamental figure in the complex crossroad of the mechanisms underlying dysfunctional angiogenesis in SSc. Binding of VEGF~165~ to vascular endothelial growth factor receptor (VEGFR)-2 induces VEGFR-2 internalization and activates signaling pathways that trigger EC proliferation, survival, and migration which are necessary for angiogenesis. VEGF~165~b binds to VEGFR-2 with the same affinity as VEGF~165~, but binding of VEGF~165~b results in an insufficient tyrosine phosphorylation/activation of VEGFR-2 and incomplete downstream signaling (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR4]\]. Owing to increased levels of VEGF~165~b, SSc-MVECs show reduced VEGFR-2 phosphorylation and impaired capillary morphogenesis in vitro \[[@CR5]\]. Accordingly, the angiogenic performance of SSc-MVECs can be improved by cotreatment with recombinant VEGF~165~ and anti-VEGF~165~b neutralizing antibodies \[[@CR5]\]. Of note in the study by Hirigoyen et al. \[[@CR1]\], when healthy dermal MVECs were incubated with SSc platelet releasates containing elevated levels of VEGF~165~b, capillary-like tube formation was significantly inhibited compared with cells treated with control platelet releasates.

It is known that the nontyrosine kinase receptor neuropilin-1 (NRP1) acts as a VEGFR-2 coreceptor in angiogenesis \[[@CR7]\]. VEGF~165~b antiangiogenic function is thought to be mechanistically related to the lack of NRP1 coreceptor binding \[[@CR4]\]. In fact, upon binding of VEGF~165~b to VEGFR-2, the absence of NRP1 cosignaling induces differential trafficking of VEGFR-2 toward proteasomal degradation \[[@CR4]\]. In SSc, besides VEGF~165~b overexpression, concomitant NRP1 downregulation because of Friend leukemia integration 1 (Fli1) transcription factor deficiency may further disturb VEGF-A/VEGFR-2 signaling \[[@CR8]\]. Finally, in this complex scenario the urokinase-type plasminogen activator receptor (uPAR), an angiogenic orchestrator acting via both VEGF-A-dependent and VEGF-A-independent mechanisms, may play a significant role because uPAR inactivation represents a master factor challenging angiogenesis in SSc \[[@CR2], [@CR9]\]. uPAR--VEGFR-2 interaction is crucial for VEGFR-2 internalization and proangiogenic signaling in ECs \[[@CR10]\]. Of note, VEGF-A-induced angiogenesis is prevented in uPAR-deficient mice, a recently proposed animal model of SSc \[[@CR9], [@CR10]\]. uPAR inactivation/deficiency may thus contribute substantially to VEGF-A/VEGFR-2 system abnormalities in SSc (Fig. [1](#Fig1){ref-type="fig"}).

Taken together, considerable evidence suggests that uncontrolled expression of the antiangiogenic VEGF~165~b isoform may take center stage in this crowded crossroad to angiogenesis in SSc. It remains to be elucidated whether the targeting of VEGF~165~b and/or VEGF-A pre-mRNA splicing machinery might represent a promising therapeutic strategy to promote effective angiogenesis in SSc patients. As pointed out in the article by Hirigoyen et al. \[[@CR1]\], a better understanding of how platelets transport and deliver uncontrolled levels of VEGF~165~b to the injured endothelium might disclose a novel pathway contributing to the SSc-related peripheral vasculopathy. Whether this mechanism is a priority pathway worth targeting warrants further studies.
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See related research by Hirigoyen et al., <http://www.arthritis-research.com/content/17/1/332>
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